The SARS-CoV-2 pandemic has presented a clinical concern for patients with multiple sclerosis (MS), whose mainstay treatment are immunosuppressive/immunomodulatory disease-modifying therapies.
1 Most approved vaccines, including the messenger RNA vaccines, induce robust humoral and cellular immune responses against the virus spike protein
2,3; however, it is still unknown whether SARS-CoV-2 vaccines confer sufficient protection in patients with MS treated with disease-modifying therapies.